Roles of PI3K/Akt and c-Jun signaling pathways in human papillomavirus type 16 oncoprotein-induced HIF-1α, VEGF, and IL-8 expression and in vitro angiogenesis in non-small cell lung cancer cells

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Zhang, Erying ^a   Feng, Xiaowei ^a   Liu, Fei ^a   Zhang, Peihua ^a   Liang, Jie ^a   Tang, Xudong ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 8; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME; PROTEIN C JUN; PROTEIN E6; PROTEIN E7; PROTEIN KINASE B; SMALL INTERFERING RNA; VASCULOTROPIN; CHROMONE DERIVATIVE; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; HIF1A PROTEIN, HUMAN; LY 290042; MORPHOLINE DERIVATIVE; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ARTICLE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOPRECIPITATION; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STABILITY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; DRUG EFFECTS; GENETICS; LUNG TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NON SMALL CELL LUNG CANCER; ONCOGENE; TUMOR CELL LINE; VASCULARIZATION; VIROLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHROMONES; GENES, JUN; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IN VITRO TECHNIQUES; INTERLEUKIN-8; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MORPHOLINES; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; REPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84904812965     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103440     Document Type: Article

References (47)

1. Torre LA, Siegel RL, Ward EM, Jemal A (2014) International Variation in Lung Cancer Mortality Rates and Trends among Women. Cancer Epidemiol Biomarkers Prev. May 16. [Epub ahead of print].
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Esti-mates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
3. Pallis AG, Syrigos KN (2013) Lung cancer in never smokers: Disease characteristics and risk factors. Crit Rev Oncol Hematol 88: 494-503.
4. Toh CK, Gao F, Lim WT, Leong SS, Fong KW, et al. (2006) Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 24: 2245-2251. (Pubitemid 46630653)
5. Sun S, Schiller JH, Gazdar AF (2007) Lung cancer in never smokers - a different disease. Nature Reviews Cancer 7: 778-790. (Pubitemid 47463669)
6. Yano T, Miura N, Takenaka T, Haro A, Okazaki H, et al. (2008) Never-smoking non small cell lung cancer as a separate entity: clinicopathologic features and survival. Cancer 113: 1012-1018.
7. Heigener DF (2011) Non-small cell lung cancer in never-smokers: a new disease entity? Onkologie 34: 202-207.
8. Syrjanen KJ (1980) Epithelial lesions suggestive of a condylomatous origin found closely associated with invasive bronchial squamous cell carcinomas. Respiration 40: 150-160.
9. Fei Y, Yang J, Hsieh WC, Wu JY, Wu TC, et al. (2006) Different human papillomavirus 16/18 infection in Chinese non-small cell lung cancer patients living in Wuhan, China. Jpn J Clin Oncol 36: 274-279. (Pubitemid 43997331)
10. Ciotti M, Giuliani L, Ambrogi V, Ronci C, Benedetto A, et al. (2006) Detection and expression of human papillomavirus oncogenes in non-small cell lung cancer. Oncol Rep 16: 183-189.
11. Wang Y, Wang A, Jiang R, Pan H, Huang B, et al. (2008) Human papillomavirus type 16 and 18 infection is associated with lung cancer patients from the central part of China. Oncol Rep 20: 333-339.
12. Hsu NY, Cheng YW, Chan IP, Ho HC, Chen CY, et al. (2009) Association between expression of human papillomavirus 16/18 E6 oncoprotein and survival in patients with stage I non-small cell lung cancer. Oncol Rep 21: 81-87.
13. Baba M, Castillo A, Koriyama C, Yanagi M, Matsumoto H, et al. (2010) Human papillomavirus is frequently detected in gefitinib-responsive lung adenocarcinomas. Oncol Rep 23: 1085-1092.
14. Aguayo F, Anwar M, Koriyama C, Castillo A, Sun Q, et al. (2010) Human papillomavirus-16 presence and physical status in lung carcinomas from Asia. Infect Agent Cancer 5: 20-26.
15. Zhang J, Wang T, Han M, Yang ZH, Liu LX, et al. (2010) Variation of Human papillomavirus 16 in cervical and lung cancers in Sichuan, China. Acta Virol 54: 247-253.
16. Krikelis D, Tzimagiorgis G, Georgiou E, Destouni C, Agorastos T, et al. (2010) Frequent presence of incomplete HPV16 E7 ORFs in lung carcinomas: memories of viral infection. J Clin Virol 49: 169-174.
17. Rezazadeh A, Laber DA, Ghim SJ, Jenson AB, Kloecker G (2009) The role of human papilloma virus in lung cancer: a review of the evidence. Am J Med Sci 338: 64-67.
18. Storey R, Joh J, Kwon A, Jenson AB, Ghim SJ, et al. (2013) Detection of Immunoglobulin G against E7 of Human Papillomavirus in Non-Small-Cell Lung Cancer. J Oncol 2013: 240164.
19. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18.
20. Jackson AL, Zhou B, Kim WY (2010) HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer. Expert Opin Ther Targets 14: 1047-1057.
21. Fleitas T, Martínez-Sales V, Vila V, Reganon E, Mesado D, et al. (2013) VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer. Clin Transl Oncol 15: 897-902.
22. Chen P, Zhu J, Liu DY, Li HY, Xu N, et al. (2014) Over-expression of survivin and VEGF in small-cell lung cancer may predict the poorer prognosis. Med Oncol 31: 775.
23. Kuo WH, Shih CM, Lin CW, Cheng WE, Chen SC, et al. (2012) Association of hypoxia inducible factor-1a polymorphisms with susceptibility to non-small-cell lung cancer. Transl Res 159: 42-50.
24. Rafrafi A, Chahed B, Kaabachi S, Kaabachi W, Maalmi H, et al. (2013) Association of IL-8 gene polymorphisms with non small cell lung cancer in Tunisia: A case control study. Hum Immunol 74: 1368-1374.
25. Gioulbasanis I, Patrikidou A, Kitikidou K, Papadimitriou K, Vlachostergios PJ, et al. (2012) Baseline plasma levels of interleukin-8 in stage IV non-small-cell lung cancer patients: relationship with nutritional status and prognosis. Nutr Cancer 64: 41-47.
26. Li G, He L, Zhang E, Shi J, Zhang Q, et al. (2011) Over-expression of human papillomavirus (HPV) type 16 oncoproteins promotes angiogenesis via enhancing HIF-1α and VEGF expression in non-small cell lung cancer cells. Cancer Lett 311: 160-170.
27. Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J, et al. (2005) Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther 4: 1465-1474. (Pubitemid 41556428)
28. Zhang Q, Tang X, Lu Q, Zhang Z, Rao J, et al. (2006) Green tea extract and (-) -epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol Cancer Ther 5: 1227-1238. (Pubitemid 43881315)
29. Tang XD, Zhou X, Zhou KY (2009) Dauricine inhibits insulin-like growth factor-I-induced hypoxia inducible factor 1alpha protein accumulation and vascular endothelial growth factor expression in human breast cancer cells. Acta Pharmacol Sin 30: 605-616.
30. Tang X, Zhang Q, Shi S, Yen Y, Li XY, et al. (2010) Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells. Int J Cancer 126: 90-103.
31. Wojtalla A, Arcaro A (2011) Targeting phosphoinositide 3-kinase signalling in lung cancer. Crit Rev Oncol Hematol 80: 278-290.
32. Okada M, Shibuya K, Sato A, Seino S, Watanabe E, et al. (2013) Specific role of JNK in the maintenance of the tumor-initiating capacity of A549 human non-small cell lung cancer cells. Oncol Rep 30: 1957-1964.
33. Tang X, Zhang Q, Nishitani J, Brown J, Shi S, et al. (2007) Over-expression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin Cancer Res 13: 2568-2576. (Pubitemid 46795128)
34. Zhang EY, Li G, He L, Shi JL, Tang XD (2012) Construction and Application of Human Papillomavirus-16 Oncoproteins E6 and E7 Plasmids with Double-Selection Markers. Progress in Modern Biomedicine 12: 6045-6050. [in Chinese].
35. Yu B, Miao ZH, Jiang Y, Li MH, Yang N, et al. (2009) c-Jun protects hypoxia-inducible factor-1αlpha from degradation via its oxygen-dependent degradation domain in a nontranscriptional manner. Cancer Res 69: 7704-7712.
36. Kazi AA, Koos RD (2007) Estrogen-induced activation of hypoxia-inducible factor-1αlpha, vascular endothelial growth factor expression, and edema in the uterus are mediated by the phosphatidylinositol 3-kinase/Akt pathway. Endocrinology 148: 2363-2374. (Pubitemid 46997054)
37. Kazi AA, Molitoris KH, Koos RD (2009) Estrogen rapidly activates the PI3K/Akt pathway and hypoxia-inducible factor 1 and induces vascular endothelial growth factor A expression in luminal epithelial cells of the rat uterus. Biol Reprod 81: 378-387.
38. Stöppler H, Malerczyk C, Block K, Aigner A, Czubayko F (2001) The human papillomavirus (HPV) 16 E6 oncoprotein leads to an increase in gene expression of the angiogenic switch molecule FGF-BP in non-immortalized human keratinocytes. Oncogene 20: 7430-7436. (Pubitemid 33078215)
39. Toussaint-Smith E, Donner DB, Roman A (2004) Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. Oncogene 23: 2988-2995. (Pubitemid 38648189)
40. Xi L, Wang S, Wang C, Xu Q, Li P, et al. (2009) The pro-angiogenic factors stimulated by human papillomavirus type 16 E6 and E7 protein in C33A and human fibroblasts. Oncol Rep 21: 25-31.
41. Karar J, Maity A (2011) PI3K/Akt/mTOR Pathway in Angiogenesis. Front Mol Neurosci 4: 51.
42. Gadgeel SM, Wozniak A (2013) Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Clin Lung Cancer 14: 322-332.
43. Seeber LM, Horrée N, Vooijs MA, Heintz AP, van der Wall E, et al. (2011) The role of hypoxia inducible factor-1alpha in gynecological cancer. Crit Rev Oncol Hematol 78: 173-184.
44. Zhang G, Dass CR, Sumithran E, Di Girolamo N, Sun LQ, et al. (2004) Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. J Natl Cancer Inst 96: 683-696. (Pubitemid 38660231)
45. Textor B, Sator-Schmitt M, Richter KH, Angel P, Schorpp-Kistner M (2006) c-Jun and JunB are essential for hypoglycemia-mediated VEGF induction. Ann N Y Acad Sci 1091: 310-318. (Pubitemid 47092246)
46. Kim MR, Choi HS, Yang JW, Park BC, Kim JA, et al. (2009) Enhancement of vascular endothelial growth factor-mediated angiogenesis in tamoxifen-resistant breast cancer cells: role of Pin1 over-expression. Mol Cancer Ther 8: 2163-2171.
47. Yin Y, Wang S, Sun Y, Matt Y, Colburn NH, et al. (2009) JNK/AP-1 pathway is involved in tumor necrosis factor-alpha induced expression of vascular endothelial growth factor in MCF7 cells. Biomed Pharmacother 63: 429-435.